Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.30 |
| ▸ | SGK1 | O00141 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17293505 | 0.90 | CXCR2 (0.42) | CXCR2HTR6KDM2BALDH1A1MEN1 | |
| SCHEMBL17293567 | 0.83 | CXCR2 (0.35) | CXCR2HTR6ALDH1A1KDM4EMAPT | |
| SCHEMBL17293468 | 0.82 | CXCR2 (0.44) | CXCR2HTR6KDM2BALDH1A1MEN1 | |
| SCHEMBL19082732 | 0.81 | STS (0.46) | MEN1KMT2AKDM4EMAPT | |
| SCHEMBL17293353 | 0.81 | CXCR2 (0.41) | CXCR2ALDH1A1KDM4EMAPTNPSR1 | |
| SCHEMBL17293354 | 0.81 | CXCR2 (0.41) | CXCR2ALDH1A1KDM4EMAPTNPSR1 | |
| SCHEMBL17293616 | 0.81 | CXCR2 (0.34) | CXCR2HTR6KDM2BALDH1A1MEN1 | |
| SCHEMBL17293266 | 0.80 | KDM4E (0.31) | ALDH1A1KDM4EMAPTNPSR1 | |
| SCHEMBL19065846 | 0.80 | KDM4E (0.31) | ALDH1A1KDM4EMAPTNPSR1 | |
| SCHEMBL5711785 | 0.80 | ALDH1A1 (0.46) | CXCR2ALDH1A1MEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | Glaxosmithline Intellectual Property Development Limited (GB) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885HTR6 873/4885KDM2B 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.